Cardiovascular Pharmacogenetics:
The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic re...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2004
|
| Schriftenreihe: | Handbook of Experimental Pharmacology
160 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis |
| Beschreibung: | 1 Online-Ressource (X, 407 p) |
| ISBN: | 9783662062142 |
| DOI: | 10.1007/978-3-662-06214-2 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046148360 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190906s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9783662062142 |9 978-3-662-06214-2 | ||
| 024 | 7 | |a 10.1007/978-3-662-06214-2 |2 doi | |
| 035 | |a (ZDB-2-SBL)978-3-662-06214-2 | ||
| 035 | |a (OCoLC)1119004413 | ||
| 035 | |a (DE-599)BVBBV046148360 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.12 |2 23 | |
| 084 | |a XI 1701 |0 (DE-625)152977:12907 |2 rvk | ||
| 245 | 1 | 0 | |a Cardiovascular Pharmacogenetics |c edited by Martin R. Wilkins |
| 246 | 1 | 3 | |a with contributions by numerous experts |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 2004 | |
| 300 | |a 1 Online-Ressource (X, 407 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Handbook of Experimental Pharmacology |v 160 | |
| 520 | |a The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis | ||
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Neurosciences | |
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Human Genetics | |
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Neurosciences | |
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Human genetics | |
| 650 | 0 | 7 | |a Kardiovaskuläre Krankheit |0 (DE-588)4024666-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakogenetik |0 (DE-588)4271255-5 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Kardiovaskuläre Krankheit |0 (DE-588)4024666-8 |D s |
| 689 | 0 | 1 | |a Pharmakogenetik |0 (DE-588)4271255-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Wilkins, Martin R. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642072918 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540402046 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783662062159 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-662-06214-2 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 940 | 1 | |q ZDB-2-SBL_2000/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031528537 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-662-06214-2 |l UBR01 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180488510767104 |
|---|---|
| any_adam_object | |
| author2 | Wilkins, Martin R. |
| author2_role | edt |
| author2_variant | m r w mr mrw |
| author_facet | Wilkins, Martin R. |
| building | Verbundindex |
| bvnumber | BV046148360 |
| classification_rvk | XI 1701 |
| collection | ZDB-2-SBL |
| ctrlnum | (ZDB-2-SBL)978-3-662-06214-2 (OCoLC)1119004413 (DE-599)BVBBV046148360 |
| dewey-full | 616.12 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12 |
| dewey-search | 616.12 |
| dewey-sort | 3616.12 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-662-06214-2 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03528nmm a2200613zcb4500</leader><controlfield tag="001">BV046148360</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783662062142</subfield><subfield code="9">978-3-662-06214-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-662-06214-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-3-662-06214-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119004413</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046148360</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cardiovascular Pharmacogenetics</subfield><subfield code="c">edited by Martin R. Wilkins</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">with contributions by numerous experts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 407 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Handbook of Experimental Pharmacology</subfield><subfield code="v">160</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurosciences</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Human Genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurosciences</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Human genetics</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kardiovaskuläre Krankheit</subfield><subfield code="0">(DE-588)4024666-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakogenetik</subfield><subfield code="0">(DE-588)4271255-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Kardiovaskuläre Krankheit</subfield><subfield code="0">(DE-588)4024666-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakogenetik</subfield><subfield code="0">(DE-588)4271255-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilkins, Martin R.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642072918</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540402046</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783662062159</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-662-06214-2</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031528537</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-662-06214-2</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046148360 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:34Z |
| institution | BVB |
| isbn | 9783662062142 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031528537 |
| oclc_num | 1119004413 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 407 p) |
| psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | Handbook of Experimental Pharmacology |
| spelling | Cardiovascular Pharmacogenetics edited by Martin R. Wilkins with contributions by numerous experts Berlin, Heidelberg Springer Berlin Heidelberg 2004 1 Online-Ressource (X, 407 p) txt rdacontent c rdamedia cr rdacarrier Handbook of Experimental Pharmacology 160 The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis Cardiology Pharmacology/Toxicology Neurosciences Neurology Human Genetics Toxicology Human genetics Kardiovaskuläre Krankheit (DE-588)4024666-8 gnd rswk-swf Pharmakogenetik (DE-588)4271255-5 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Kardiovaskuläre Krankheit (DE-588)4024666-8 s Pharmakogenetik (DE-588)4271255-5 s DE-604 Wilkins, Martin R. edt Erscheint auch als Druck-Ausgabe 9783642072918 Erscheint auch als Druck-Ausgabe 9783540402046 Erscheint auch als Druck-Ausgabe 9783662062159 https://doi.org/10.1007/978-3-662-06214-2 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Cardiovascular Pharmacogenetics Cardiology Pharmacology/Toxicology Neurosciences Neurology Human Genetics Toxicology Human genetics Kardiovaskuläre Krankheit (DE-588)4024666-8 gnd Pharmakogenetik (DE-588)4271255-5 gnd |
| subject_GND | (DE-588)4024666-8 (DE-588)4271255-5 (DE-588)4143413-4 |
| title | Cardiovascular Pharmacogenetics |
| title_alt | with contributions by numerous experts |
| title_auth | Cardiovascular Pharmacogenetics |
| title_exact_search | Cardiovascular Pharmacogenetics |
| title_full | Cardiovascular Pharmacogenetics edited by Martin R. Wilkins |
| title_fullStr | Cardiovascular Pharmacogenetics edited by Martin R. Wilkins |
| title_full_unstemmed | Cardiovascular Pharmacogenetics edited by Martin R. Wilkins |
| title_short | Cardiovascular Pharmacogenetics |
| title_sort | cardiovascular pharmacogenetics |
| topic | Cardiology Pharmacology/Toxicology Neurosciences Neurology Human Genetics Toxicology Human genetics Kardiovaskuläre Krankheit (DE-588)4024666-8 gnd Pharmakogenetik (DE-588)4271255-5 gnd |
| topic_facet | Cardiology Pharmacology/Toxicology Neurosciences Neurology Human Genetics Toxicology Human genetics Kardiovaskuläre Krankheit Pharmakogenetik Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-662-06214-2 |
| work_keys_str_mv | AT wilkinsmartinr cardiovascularpharmacogenetics AT wilkinsmartinr withcontributionsbynumerousexperts |